We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe harbor provisions of the PSLRA. Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmaceutical industry, and other legal, regulatory and economic developments. LabCorp and Covance undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. These statements are based on current plans, estimates and projections, and therefore, you are cautioned not to place undue reliance on them. ("Covance"), the management of either such company or the proposed transaction between LabCorp and Covance, involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These statements, as they relate to Laboratory Corporation of America Holdings ("LabCorp") or Covance Inc. This communication contains "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. Information on Covance's solutions, recent press releases, and SEC filings can be obtained through its website at Cautionary Statement Regarding Forward Looking Statements The company, headquartered in Princeton, New Jersey, has annual revenues greater than $2.5 billion and more than 12,500 employees located in over 60 countries. To learn more about LabCorp, visit its website at: About CovanceĬovance, the world's most comprehensive drug development company and a leader in nutritional analysis, is dedicated to advancing healthcare and delivering Solutions Made Real ™. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. LabCorp conducts clinical trials testing through its LabCorp Clinical Trials division. LabCorp furthers its scientific expertise and innovative clinical testing technology through its LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox, and Endocrine Sciences. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. Laboratory Corporation of America ® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. The transaction, which is expected to close on or about February 19, 2015, remains subject to the satisfaction of the closing conditions set forth in the merger agreement. ![]() ![]() More than 99 percent of votes cast at the special meeting were in favor of the transaction, representing more than 78 percent of all outstanding Covance shares.Īs previously announced on November 3, 2014, the Boards of Directors of both Covance and LabCorp approved a definitive agreement under which Covance stockholders will receive $75.76 in cash and 0.2686 LabCorp shares for each Covance share they own. (NYSE: CVD) (Covance) and Laboratory Corporation of America ® Holdings (NYSE: LH) (LabCorp ®) jointly announced that Covance's stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Covance by LabCorp at the special meeting of Covance stockholders held earlier today.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |